ARID1A and endometrial carcinoma: These results are in good agreement with those reported earlier by Levine and collaborators [39], who analyzed 373 endometrial carcinomas and found extensive copy number alterations, few DNA methylation changes, low estrogen receptor/progesterone receptor levels, and frequent POLE, TP53, PTEN, CTNNB1, PIK3CA, ARID1A, and KRAS mutations, plus novel mutations in the chromatin remodeling complex gene ARID5B (see also below).